USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
16 Nov 2021 | 03:45 PM GMT

Digital Health for Multiple Sclerosis (MS)

Anchored by:

Nader Alaghband
Co-Founder & CEO
AMPERSAND HEALTH
Malin Johansson
Vice President
NOVO NORDISK

Participants:

Malin Johansson Vice PresidentNovo Nordisk
Malin Johansson
Vice PresidentNovo Nordisk
Nader Alaghband Co-Founder & CEOAmpersand Health
Nader Alaghband
Co-Founder & CEOAmpersand Health
Alan Gilbert Chief Executive Officer (CEO)BeCareLink
Alan Gilbert
Chief Executive Officer (CEO)BeCareLink
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Eliza Silvester Senior PrincipalIQVIA
Eliza Silvester
Senior PrincipalIQVIA
George Platings Director of Business DevelopmentuMotif
George Platings
Director of Business DevelopmentuMotif
Ivan Jurisic Head of ProductPatients Influence
Ivan Jurisic
Head of ProductPatients Influence
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Laura Gunn Vice President Medical AffairsAdaptimmune
Laura Gunn
Vice President Medical AffairsAdaptimmune
Peter Hunter Johnston ConsultantblueBriX
Peter Hunter Johnston
ConsultantblueBriX
Radhika Kamalia Chief Of Staff to the CEOAmpersand Health
Radhika Kamalia
Chief Of Staff to the CEOAmpersand Health
Steven Paalz Web DeveloperNight Market
Steven Paalz
Web DeveloperNight Market
TS
Tomas Stack HCPRoche Hoffman
TS
Tomas Stack
HCPRoche Hoffman

About this Meeting

More than 2.5M people are living with MS worldwide. However, pharmacological developments over the past decade have been relatively slow and MS is currently incurable. Plus, MS presents in highly heterogeneous ways from patient to patient, which makes early diagnosis and monitoring disease progression very challenging. How can we leverage digital tech to address the main pain points & unmet needs in the MS patient journey?

 Digital tools could play a key role in remote diagnosis, remote physical therapy, neurological assessment for early identification of relapses, and also in addressing the most common comorbidities like depression, anxiety or hypertension. Join us in this informal meeting where we will discuss:  

  •  Current Digital Health solutions for MS patients & unmet needs: what have been the most successful use cases so far and why? What are the pain points in the patient journey that can be addressed by digital health tools (e.g diagnosis, comorbidities, continuous neurological assessment, etc)? What should we double down on? 
  •  Commercialisation models: what are the most attractive routes to market for digital health companies in the space (partnerships with pharma, medtech, payers, D2C, hospitals, etc)? 
  •  Adoption: what are the current adoption levels of digital health solutions for MS? How do we get care teams and patients to use these tools? What are the barriers and challenges when integrating these tools into HCPs workflows?